results from cartitude-4: cilta-cel for lenalidomide-refractory multiple myeloma
Published 1 year ago • 389 plays • Length 8:16Download video MP4
Download video MP3
Similar videos
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
3:07
cilta-cel in lenalidomide-refractory mm patients: updates from cohort a of the cartitude-2 trial
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
4:04
the future of myeloma treatment and the possibility of cure
-
18:33
car t-cell therapy: reprogramming the immune system to treat cancer | rob weinkove | tedxtauranga
-
1:00:30
what’s next in car t cell therapy with dr. michel sadelain
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
1:54
cilta-cel vs standard of care in functional high-risk myeloma: findings from cartitude-4
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
1:57
treatment options for patients with multiple myeloma refractory to lenalidomide
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
2:09
cartitude-1: cilta-cel improves hrqol for patients with myeloma
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
1:30
cartitude-1: promising initial results of cilta-cel for myeloma
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
2:18
a cost per responder analysis of cilta-cel vs physician's choice in lenalidomide-refractory mm
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
1:07
updated results from cartitude-1